The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting growing optimism within the biotechnology sector, Citizens has raised its price target for Protagonist Therapeutics from $137 to $165 while maintaining a Market Outperform rating. The firm estimates $8 million in Q2 royalty revenue, driven by prescription volumes for the drug Icotyde that have significantly exceeded initial expectations. This upward adjustment is based on accelerated royalty projections and higher peak sales estimates as clinical and commercial confidence in the drug's market position strengthens.
This bullish outlook comes as biotech firms with royalty-based revenue models gain traction; for instance, peer company Royalty Pharma (RPRX) reported a 9% growth in portfolio receipts in its most recent quarterly filing. Compared to sector peers, the target hike for Protagonist underscores analyst conviction in Icotyde's ability to capture market share, mirroring a broader trend where specialized drug sales have shown robust growth this year per market data.
Regarding stock performance, PTGX stood at $132.02 (at close 2026-07-16), indicating substantial upside potential relative to the new target. With no immediate pharmaceutical-specific catalysts in the upcoming economic calendar, traders will likely watch support levels near $131.35, the low reached during the last trading session, to gauge the sustainability of the momentum generated by the Citizens report.